The affected lots of the voluntary recall by Legacy Pharmaceutical Packaging are the following: NDC 68645-494-54, losartan potassium tablets USP 50 mg, 30 count, Legacy Lot 180190, expires on 10/2020. NDC 68645-494-54, losartan potassium tablets USP 50 mg, 30 count, Legacy Lot 181598, expires on 02/2021.

On April 26, 2021, the FDA designated the recalls Class II, communicating use of the drug may cause temporary or medically reversible adverse health consequences or a remote possibility of serious harm. Losartan is a prescription drug used to treat high blood pressure.

Losartan potassium is a hypertension treatment. Research suggests that the medication is safe and effective for most people. People may experience mild side effects, such as dizziness, in the early stages of treatment. People who experience severe or persistent side effects should contact their doctor right away.

Torrent Pharmaceuticals, which also goes by Torrent Pharma, markets the drug. Recently, the company voluntarily withdrew some batches of Losartan from the market because they contained traces of an impurity at levels that the Food and Drug Administration (FDA) consider unsafe.

Lupin discontinued the marketing of Irbesartan and Irbesartan and HCTZ tabs in Jan 2021.

On September 13, 2021, Jubilant Cadista Pharmaceuticals announced a market withdrawal of all unexpired lots of Losartan Potassium as well as Losartan Potassium and Hydrochlorothiazide distributed under the Cadista label.

If it continues for a long time, the heart and arteries may not function properly. This can damage the blood vessels of the brain, heart, and kidneys, resulting in a stroke, heart failure, or kidney failure.

There are several other angiotensin receptor blockers that work in the same way as losartan. They include candesartan, irbesartan and valsartan. There are other types of blood pressure-lowering medicines: calcium channel blockers – for example amlodipine.

It’s recalling: All batches of irbesartan tablets USP 75mg, 150mg and 300mg. All batches of irbesartan and hydrochlorothiazide tablets USP, 150mg/12.5mg and 300mg/12.5mg.

FDA: “Lupin Pharmaceuticals, Inc. Issues Voluntarily Nationwide Recall of All Irbesartan Tablets and Irbesartan and Hydrochlorothiazide Tablets Due to Potential Presence of N-nitrosoirbesartan Impurity,” “Reporting Serious Problems to FDA.”

Conclusions: Irbesartan is an appropriate substitution for valsartan or losartan.

Olmesartan is available in convenient combination tablets: olmesartan/HCTZ and olmesartan/amlodipine/HCTZ. Olmesartan is better than losartan at lowering blood pressure and generally provides good 24-hour coverage.

Drug recalls are actions taken by a firm to remove a product from the market and may be conducted on a firm’s own initiative, by FDA request, or by FDA order under statutory authority.

A Food and Drug Administration recall of a heart medication due to a cancer-causing chemical now includes two blood pressure medications.

The FDA announced the recall on its website Tuesday. The move is due to the detection of a probable human carcinogen known as NDEA, which has been found in valsartan API, the FDA said.

Teva Pharmaceuticals has issued a voluntary recall of its amlodipine/valsartan combination tablets and amlodipine/valsartan/hydrochlorothiazide combination tablets, both used to treat high blood pressure, according to the FDA. The FDA announced the recall on its website Tuesday.